SLCO1B1 polymorphism associated with methotrexate disposition and clinical outcome
- VernacularTitle:SLCO1 B1基因多态性对甲氨蝶呤治疗的影响
- Author:
Ping GAO
1
;
Hua-Nian ZHANG
Author Information
1. 武汉市儿童医院 药学部
- Keywords:
SLCO1 B1;
methotrexate;
genetic polymorphism;
pharmaco-kinetic;
adverse drug reaction
- From:
The Chinese Journal of Clinical Pharmacology
2014;(8):730-732
- CountryChina
- Language:Chinese
-
Abstract:
Organic anion transporting polypeptide 1B1 ( OATP1B1, en-coded by SLCO1B1 gene) plays a crucial role in the hepatic uptake of many endogenous compounds and xenobiotics.It has been demonstrated that SLCO1B1 polymorphism could change the pharmacokinetics charac-teristics of many clinically used drugs , which has influenced their out-come and safety.However , inter-individual variant of methotrexate re-sults in vastly different clinical effectiveness and toxicity.Herein, we re-view the current knowledge about this topic to provide theoretical guid-ance for the clinical use of methotrexate.
